1. Home
  2. CRSP vs HWC Comparison

CRSP vs HWC Comparison

Compare CRSP & HWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$53.57

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo Hancock Whitney Corporation

HWC

Hancock Whitney Corporation

HOLD

Current Price

$66.34

Market Cap

5.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
HWC
Founded
2013
1883
Country
Switzerland
United States
Employees
N/A
3627
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.2B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRSP
HWC
Price
$53.57
$66.34
Analyst Decision
Buy
Strong Buy
Analyst Count
17
6
Target Price
$70.29
$77.67
AVG Volume (30 Days)
1.6M
735.3K
Earning Date
05-11-2026
04-21-2026
Dividend Yield
N/A
3.00%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
N/A
Revenue This Year
$807.72
$11.59
Revenue Next Year
$172.52
$4.42
P/E Ratio
N/A
$12.48
Revenue Growth
9169.85
N/A
52 Week Low
$33.03
$52.89
52 Week High
$78.48
$75.43

Technical Indicators

Market Signals
Indicator
CRSP
HWC
Relative Strength Index (RSI) 52.63 48.87
Support Level $50.91 $66.40
Resistance Level $60.45 $68.09
Average True Range (ATR) 2.72 1.65
MACD -0.31 -0.19
Stochastic Oscillator 42.74 11.48

Price Performance

Historical Comparison
CRSP
HWC

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About HWC Hancock Whitney Corporation

Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.

Share on Social Networks: